Tengion

Clinical-stage biotechnology company developing neo-organs and neo-tissues.

Launch date

2003

Market cap

Enterprise valuation

AUD44m (Public information from Sep 2024)

Washington District of Columbia (HQ)

Date	Investors	Amount	Round
-	Deerfield Partners Safeguard Scientifics J&J Development Oxford Finance	N/A	-
Aug 2005	Oak Investment Partners HealthCap Johnson & Johnson Development Corporation L Capital Partners	$39.0m	Series A
Jun 2006	Bain Capital Oak Investment Partners HealthCap Quaker Bio Ventures Johnson & Johnson Development Corporation L Capital Partners	$50.0m	Series B
Oct 2007	Deerfield Capital Management	$33.0m	Series C
Nov 2008	N/A	$21.0m	Series C
Apr 2010	N/A	N/A	IPO
Mar 2011	Celgene	$31.4m	Post IPO Equity
Oct 2012	N/A	$15.0m	Post IPO Debt
Aug 2013	N/A	$74.3m	Post IPO Debt
Dec 2014*	N/A	N/A	Bankruptcy
Total Funding		AUD221m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Tengion